A Dallas County court granted a motion Friday to strike the Texas Chief law officer's intervention in a case where a physician is battling to continue supplying gender-affirming upkeep to transgender young people at Kid's Medical Center. This decision essentially removes Ken Paxton's office from the situation.
The decision was an added success for Dr. Ximena Lopez and her attorneys. They argued Paxton's office had no authority to intervene in a case about a physician's judgment in providing treatment that drops within the medical criterion of standard therapy.
After a two-hour hearing, Judge Melissa Bellan agreed with Lopez's lawyers. Saying she did not find a justiciable interest or the Attorney general of the United States's office or the State of Texas might show they have authority to act upon part of any individual in this case.
The same judge had already approved a short-lived limiting order and a momentary injunction last month, enabling Dr. Lopez and various other Children's doctors to proceed with supplying gender-affirming treatment.
Paxton's office then stepped in. Lawyers for Paxton argued Friday they wanted to yield professionals in the event to debate whether gender-affirming treatments could be considered youngster misuse in particular conditions.
Paxton issued an opinion in February stating that some gender-affirming treatments could be thought about child abuse. Prompting Gov. Greg Abbott to order the Department of Family and Protective Providers to examine "any reported circumstances of these abusive treatments in the State of Texas." The state is currently battling two legal actions from households of children receiving such treatment in Texas that state DFPS investigated.
Lopez founded the program GENECIS in 2012, referred to as the initial therapy clinic in the Southwest for kids with gender dysphoria. Her petition declared the center was mistakenly closed down by UT Southwestern, a relocation widely covered by the press in November. According to the petition, she asserts UT Southwestern administrators told her that she could supply the age of puberty blockers and hormonal agent therapy to existing trans-patients yet not new clients.
